Celgene and Pharmstandard scored exits as part of an initial public offering in which immuno-oncology company Jounce floated above its range.
Pharmaceutical companies Celgene and Pharmstandard recorded an exit on Friday as US-based immuno-oncology therapy developer Jounce Therapeutics went public in a $102m initial public offering.
Jounce issued 6.4 million shares priced at $16 each, above the $13 to $15 range it set earlier this month. The company had originally filed for a $75m IPO just over three weeks ago.
Founded in 2012, Jounce is developing immunotherapies based on its Translational Science Platform that will fight cancer by targeting diverse…
